Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone.
Peptide B
Healing & Recovery
The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.
Typical vial
5 mg
Typical dose
200-500 mcg
Half-life
~15-30 minutes (short half-life typical of small peptides)
FDA status
Not FDA approved for human use.
Typical vial
10 mg
Typical dose
2000-5000 mcg
Half-life
Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)
FDA status
Not FDA approved for any human or veterinary use. No clinica…
KPV effects
TB-500 Fragment 17-23 effects
KPV side effects
TB-500 Fragment 17-23 side effects
KPV dosing ranges
Gut inflammation support
200-500 mcg · Once or twice daily (oral or SubQ) · 4-8 weeks
Systemic anti-inflammatory
200-500 mcg · Once daily (SubQ) · 4-6 weeks
TB-500 Fragment 17-23 dosing ranges
Injury recovery (extrapolated)
2-5 mg · Twice weekly SubQ · 4-6 weeks
Tendon/ligament support (extrapolated)
2-5 mg · Twice weekly SubQ · 4-8 weeks
Loading phase (anecdotal)
5 mg · Twice weekly for 2-3 weeks · Then maintenance
KPV: Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. Typical dose 200-500 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.
Stacking KPV with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
KPV is typically dosed: Once or twice daily (oral or SubQ) for Gut inflammation support; Once daily (SubQ) for Systemic anti-inflammatory. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).
KPV: Not FDA approved for human use. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free